Skip to main content
. 2017 Jan 16;7:688. doi: 10.3389/fimmu.2016.00688

Figure 3.

Figure 3

The innate CD8 T cell subset is partially restored in patients having achieved complete cytogenetic remission with imatinib mesylate (IM) therapy. (A) Partial restoration of the pool of innate CD8(+) T cells in chronic myeloid leukemia (CML)-IM. Frequency (mean ± SEM) of killer cell Ig-like receptor (KIR)/NKG2A(+) Eomes(+) cells among total CD8(+) CD3(+) cells (left panel) in CML-CP and CML-IM patients. Dotted lines represent mean frequency values in healthy donor (HD). Mean fluorescence intensity (MFI) of Eomes expression (mean ± SEM, right panel) in KIR/NKG2A(+) CD8(+) T cells from CML-CP and CML-IM patients were analyzed after gating on KIR/NKG2A(+) CD8(+) CD3(+) cells. MFI of Eomes expression was normalized on MFI of Eomes from total KIR/NKG2A(−) CD3(−) cells. Dotted lines represent mean relative MFI Eomes values in HD. (B) Partial restoration of IL-12 + IL-18-induced IFN-γ expression by innate T CD8(+) cells from CML-IM patients. For details, see the caption of Figure 2A. Histograms represent frequencies (means ± SEM) of IFN-γ-expressing cells among KIR/NKG2A(+) Eomes(+) CD8(+) T cells after IL-12 + IL-18 stimulation in each group of patients and HD. Without stimulation, frequency of IFN-γ-expressing cells was lower than 0.1%. (C) Complete restoration of natural cytotoxic activity by innate T CD8(+) cells from CML-IM patients. CD107a degranulation/expression after CD16 triggering (for details, see Section “Materials and Methods”) in KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+) cells was analyzed by flow cytometry among peripheral blood mononuclear cells preincubated for 48 h with IL-15. Data (means ± SEM) are expressed as frequencies of CD107a-expressing cells in KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+) cells from CML-CP and CML-IM patients. Dotted lines represent mean frequency values in HD. (A–C) Statistical significance was determined by the two-tailed Mann–Whitney non-parametric test (comparisons between HD and CML-CP patient groups) or the two-tailed Wilcoxon non-parametric test [comparisons between KIR/NKG2A(+) Eomes(+) CD8(+) CD3(+) cells and KIR/NKG2A(−) Eomes(+) CD8(+) CD3(+) cells from HD or CML-CP patient groups]. *p < 0.05; **p < 0.01.